ING5‐mediated antineuroblastoma effects of suberoylanilide hydroxamic acid

Neuroblastoma is the most common extracranial solid neuroendocrine cancer and is one of the leading causes of death in children. To improve clinical outcomes and prognosis, discovering new promising drugs and targeted medicine is essential. We found that applying Suberoylanilide hydroxamic acid (SAH...

Full description

Saved in:
Bibliographic Details
Published inCancer medicine (Malden, MA) Vol. 7; no. 9; pp. 4554 - 4569
Main Authors Wu, Ji‐cheng, Jiang, Hua‐mao, Yang, Xiang‐hong, Zheng, Hua‐chuan
Format Journal Article
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.09.2018
John Wiley and Sons Inc
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Neuroblastoma is the most common extracranial solid neuroendocrine cancer and is one of the leading causes of death in children. To improve clinical outcomes and prognosis, discovering new promising drugs and targeted medicine is essential. We found that applying Suberoylanilide hydroxamic acid (SAHA; Vorinostat, a histone deacetylase inhibitor) and MG132 (a proteasome inhibitor) to SH‐SY5Y cells synergistically suppressed proliferation, glucose metabolism, migration, and invasion and induced apoptosis and cell cycle arrest. These effects occurred both concentration and time dependently and were associated with the effects observed with inhibitor of growth 5 (ING5) overexpression. SAHA and MG132 treatment increased the expression levels of ING5, PTEN, p53, Caspase‐3, Bax, p21, and p27 but decreased the expression levels of 14‐3‐3, MMP‐2, MMP‐9, ADFP, Nanog, c‐myc, CyclinD1, CyclinB1, and Cdc25c concentration dependently, similar to ING5. SAHA may downregulate miR‐543 and miR‐196‐b expression to enhance the translation of ING5 protein, which promotes acetylation of histones H3 and H4. All three proteins (ING5 and acetylated histones H3 and H4) were recruited to the promoters of c‐myc, Nanog, CyclinD1, p21, and p27 for complex formation, thereby regulating the mRNA expression of downstream genes. ING5 overexpression and SAHA and/or MG132 administration inhibited tumor growth in SH‐SY5Y cells by suppressing proliferation and inducing apoptosis. The expression of acetylated histones H3 and ING5 may be closely linked to the tumor size of neuroblastomas. In summary, SAHA and/or MG132 can synergistically suppress the malignant phenotypes of neuroblastoma cells through the miRNA‐ING5‐histone acetylation axis and via proteasomal degradation, respectively. Therefore, the two drugs may serve as potential treatments for neuroblastoma. The treatment with SAHA (a histone deacetylase inhibitor) and MG132 (a proteasome inhibitor) synergistically suppressed proliferation, glucose metabolism, migration, and invasion, and induced apoptosis and cell cycle arrest of neuroblastoma cells in both concentration‐ and time‐dependent manners. SAHA and MG132 treatment upregulates the expression of ING5, which has the same effects as SAHA. SAHA may downregulate miR‐543 and miR‐196‐b expression to enhance the translation of ING5 protein. SAHA and ING5 overexpression promote the acetylation of histones H3 and H4. ING5 and acetyl‐histones H3 and H4 were recruited to the promoters of Nanog, c‐myc, CyclinD1, p21, and p27 for complex formation, which thereby regulates the mRNA expression of the latter genes. ING5 overexpression, SAHA, and/or MG132 administration suppressed tumor growth in SY5Y cells by inhibiting proliferation and inducing apoptosis. Expression of acetyl‐histone H3 and ING5 may be closely linked to tumor size of neuroblastoma.
AbstractList Abstract Neuroblastoma is the most common extracranial solid neuroendocrine cancer and is one of the leading causes of death in children. To improve clinical outcomes and prognosis, discovering new promising drugs and targeted medicine is essential. We found that applying Suberoylanilide hydroxamic acid (SAHA; Vorinostat, a histone deacetylase inhibitor) and MG132 (a proteasome inhibitor) to SH‐SY5Y cells synergistically suppressed proliferation, glucose metabolism, migration, and invasion and induced apoptosis and cell cycle arrest. These effects occurred both concentration and time dependently and were associated with the effects observed with inhibitor of growth 5 (ING5) overexpression. SAHA and MG132 treatment increased the expression levels of ING5, PTEN, p53, Caspase‐3, Bax, p21, and p27 but decreased the expression levels of 14‐3‐3, MMP‐2, MMP‐9, ADFP, Nanog, c‐myc, CyclinD1, CyclinB1, and Cdc25c concentration dependently, similar to ING5. SAHA may downregulate miR‐543 and miR‐196‐b expression to enhance the translation of ING5 protein, which promotes acetylation of histones H3 and H4. All three proteins (ING5 and acetylated histones H3 and H4) were recruited to the promoters of c‐myc, Nanog, CyclinD1, p21, and p27 for complex formation, thereby regulating the mRNA expression of downstream genes. ING5 overexpression and SAHA and/or MG132 administration inhibited tumor growth in SH‐SY5Y cells by suppressing proliferation and inducing apoptosis. The expression of acetylated histones H3 and ING5 may be closely linked to the tumor size of neuroblastomas. In summary, SAHA and/or MG132 can synergistically suppress the malignant phenotypes of neuroblastoma cells through the miRNA‐ING5‐histone acetylation axis and via proteasomal degradation, respectively. Therefore, the two drugs may serve as potential treatments for neuroblastoma.
Abstract Neuroblastoma is the most common extracranial solid neuroendocrine cancer and is one of the leading causes of death in children. To improve clinical outcomes and prognosis, discovering new promising drugs and targeted medicine is essential. We found that applying Suberoylanilide hydroxamic acid (SAHA; Vorinostat, a histone deacetylase inhibitor) and MG132 (a proteasome inhibitor) to SH‐SY5Y cells synergistically suppressed proliferation, glucose metabolism, migration, and invasion and induced apoptosis and cell cycle arrest. These effects occurred both concentration and time dependently and were associated with the effects observed with inhibitor of growth 5 (ING5) overexpression. SAHA and MG132 treatment increased the expression levels of ING5, PTEN, p53, Caspase‐3, Bax, p21, and p27 but decreased the expression levels of 14‐3‐3, MMP‐2, MMP‐9, ADFP, Nanog, c‐myc, CyclinD1, CyclinB1, and Cdc25c concentration dependently, similar to ING5. SAHA may downregulate miR‐543 and miR‐196‐b expression to enhance the translation of ING5 protein, which promotes acetylation of histones H3 and H4. All three proteins (ING5 and acetylated histones H3 and H4) were recruited to the promoters of c‐myc, Nanog, CyclinD1, p21, and p27 for complex formation, thereby regulating the mRNA expression of downstream genes. ING5 overexpression and SAHA and/or MG132 administration inhibited tumor growth in SH‐SY5Y cells by suppressing proliferation and inducing apoptosis. The expression of acetylated histones H3 and ING5 may be closely linked to the tumor size of neuroblastomas. In summary, SAHA and/or MG132 can synergistically suppress the malignant phenotypes of neuroblastoma cells through the miRNA‐ING5‐histone acetylation axis and via proteasomal degradation, respectively. Therefore, the two drugs may serve as potential treatments for neuroblastoma.
Neuroblastoma is the most common extracranial solid neuroendocrine cancer and is one of the leading causes of death in children. To improve clinical outcomes and prognosis, discovering new promising drugs and targeted medicine is essential. We found that applying Suberoylanilide hydroxamic acid (SAHA; Vorinostat, a histone deacetylase inhibitor) and MG132 (a proteasome inhibitor) to SH‐SY5Y cells synergistically suppressed proliferation, glucose metabolism, migration, and invasion and induced apoptosis and cell cycle arrest. These effects occurred both concentration and time dependently and were associated with the effects observed with inhibitor of growth 5 (ING5) overexpression. SAHA and MG132 treatment increased the expression levels of ING5, PTEN, p53, Caspase‐3, Bax, p21, and p27 but decreased the expression levels of 14‐3‐3, MMP‐2, MMP‐9, ADFP, Nanog, c‐myc, CyclinD1, CyclinB1, and Cdc25c concentration dependently, similar to ING5. SAHA may downregulate miR‐543 and miR‐196‐b expression to enhance the translation of ING5 protein, which promotes acetylation of histones H3 and H4. All three proteins (ING5 and acetylated histones H3 and H4) were recruited to the promoters of c‐myc, Nanog, CyclinD1, p21, and p27 for complex formation, thereby regulating the mRNA expression of downstream genes. ING5 overexpression and SAHA and/or MG132 administration inhibited tumor growth in SH‐SY5Y cells by suppressing proliferation and inducing apoptosis. The expression of acetylated histones H3 and ING5 may be closely linked to the tumor size of neuroblastomas. In summary, SAHA and/or MG132 can synergistically suppress the malignant phenotypes of neuroblastoma cells through the miRNA‐ING5‐histone acetylation axis and via proteasomal degradation, respectively. Therefore, the two drugs may serve as potential treatments for neuroblastoma. The treatment with SAHA (a histone deacetylase inhibitor) and MG132 (a proteasome inhibitor) synergistically suppressed proliferation, glucose metabolism, migration, and invasion, and induced apoptosis and cell cycle arrest of neuroblastoma cells in both concentration‐ and time‐dependent manners. SAHA and MG132 treatment upregulates the expression of ING5, which has the same effects as SAHA. SAHA may downregulate miR‐543 and miR‐196‐b expression to enhance the translation of ING5 protein. SAHA and ING5 overexpression promote the acetylation of histones H3 and H4. ING5 and acetyl‐histones H3 and H4 were recruited to the promoters of Nanog, c‐myc, CyclinD1, p21, and p27 for complex formation, which thereby regulates the mRNA expression of the latter genes. ING5 overexpression, SAHA, and/or MG132 administration suppressed tumor growth in SY5Y cells by inhibiting proliferation and inducing apoptosis. Expression of acetyl‐histone H3 and ING5 may be closely linked to tumor size of neuroblastoma.
Neuroblastoma is the most common extracranial solid neuroendocrine cancer and is one of the leading causes of death in children. To improve clinical outcomes and prognosis, discovering new promising drugs and targeted medicine is essential. We found that applying Suberoylanilide hydroxamic acid (SAHA; Vorinostat, a histone deacetylase inhibitor) and MG132 (a proteasome inhibitor) to SH‐SY5Y cells synergistically suppressed proliferation, glucose metabolism, migration, and invasion and induced apoptosis and cell cycle arrest. These effects occurred both concentration and time dependently and were associated with the effects observed with inhibitor of growth 5 (ING5) overexpression. SAHA and MG132 treatment increased the expression levels of ING5, PTEN, p53, Caspase‐3, Bax, p21, and p27 but decreased the expression levels of 14‐3‐3, MMP‐2, MMP‐9, ADFP, Nanog, c‐myc, CyclinD1, CyclinB1, and Cdc25c concentration dependently, similar to ING5. SAHA may downregulate miR‐543 and miR‐196‐b expression to enhance the translation of ING5 protein, which promotes acetylation of histones H3 and H4. All three proteins (ING5 and acetylated histones H3 and H4) were recruited to the promoters of c‐myc, Nanog, CyclinD1, p21, and p27 for complex formation, thereby regulating the mRNA expression of downstream genes. ING5 overexpression and SAHA and/or MG132 administration inhibited tumor growth in SH‐SY5Y cells by suppressing proliferation and inducing apoptosis. The expression of acetylated histones H3 and ING5 may be closely linked to the tumor size of neuroblastomas. In summary, SAHA and/or MG132 can synergistically suppress the malignant phenotypes of neuroblastoma cells through the miRNA‐ING5‐histone acetylation axis and via proteasomal degradation, respectively. Therefore, the two drugs may serve as potential treatments for neuroblastoma.
Neuroblastoma is the most common extracranial solid neuroendocrine cancer and is one of the leading causes of death in children. To improve clinical outcomes and prognosis, discovering new promising drugs and targeted medicine is essential. We found that applying Suberoylanilide hydroxamic acid (SAHA; Vorinostat, a histone deacetylase inhibitor) and MG132 (a proteasome inhibitor) to SH-SY5Y cells synergistically suppressed proliferation, glucose metabolism, migration, and invasion and induced apoptosis and cell cycle arrest. These effects occurred both concentration and time dependently and were associated with the effects observed with inhibitor of growth 5 (ING5) overexpression. SAHA and MG132 treatment increased the expression levels of ING5, PTEN, p53, Caspase-3, Bax, p21, and p27 but decreased the expression levels of 14-3-3, MMP-2, MMP-9, ADFP, Nanog, c-myc, CyclinD1, CyclinB1, and Cdc25c concentration dependently, similar to ING5. SAHA may downregulate miR-543 and miR-196-b expression to enhance the translation of ING5 protein, which promotes acetylation of histones H3 and H4. All three proteins (ING5 and acetylated histones H3 and H4) were recruited to the promoters of c-myc, Nanog, CyclinD1, p21, and p27 for complex formation, thereby regulating the mRNA expression of downstream genes. ING5 overexpression and SAHA and/or MG132 administration inhibited tumor growth in SH-SY5Y cells by suppressing proliferation and inducing apoptosis. The expression of acetylated histones H3 and ING5 may be closely linked to the tumor size of neuroblastomas. In summary, SAHA and/or MG132 can synergistically suppress the malignant phenotypes of neuroblastoma cells through the miRNA-ING5-histone acetylation axis and via proteasomal degradation, respectively. Therefore, the two drugs may serve as potential treatments for neuroblastoma.
Author Zheng, Hua‐chuan
Yang, Xiang‐hong
Wu, Ji‐cheng
Jiang, Hua‐mao
AuthorAffiliation 2 Department of Pathology Shengjing Hospital of China Medical University Shenyang China
1 Tumor Basic and Translational Laboratory The First Affiliated Hospital of Jinzhou Medical University Jinzhou China
AuthorAffiliation_xml – name: 1 Tumor Basic and Translational Laboratory The First Affiliated Hospital of Jinzhou Medical University Jinzhou China
– name: 2 Department of Pathology Shengjing Hospital of China Medical University Shenyang China
Author_xml – sequence: 1
  givenname: Ji‐cheng
  surname: Wu
  fullname: Wu, Ji‐cheng
  organization: The First Affiliated Hospital of Jinzhou Medical University
– sequence: 2
  givenname: Hua‐mao
  surname: Jiang
  fullname: Jiang, Hua‐mao
  organization: The First Affiliated Hospital of Jinzhou Medical University
– sequence: 3
  givenname: Xiang‐hong
  surname: Yang
  fullname: Yang, Xiang‐hong
  organization: Shengjing Hospital of China Medical University
– sequence: 4
  givenname: Hua‐chuan
  orcidid: 0000-0001-9655-6940
  surname: Zheng
  fullname: Zheng, Hua‐chuan
  email: zheng_huachuan@hotmail.com
  organization: The First Affiliated Hospital of Jinzhou Medical University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30091530$$D View this record in MEDLINE/PubMed
BookMark eNp1kc9uEzEQhy3UipbQAy-AVuLEIa3_rjcXpCqCEim0FzhbY3vcOtpdF-8ukBuPwDPyJDhNqdpDffHI_vSNPb9X5KBPPRLyhtFTRik_c9DJU1YL-YIccyrVXJf64FF9RE6GYUPL0pTXmr0kR4LSBVOCHpP16vJC_f39p0MfYURfQT_GHqecbAvDmDqoMAR041ClUA2TxZy2LfSxjR6rm63P6Rd00VXgon9NDgO0A57c7zPy7dPHr8vP8_XVxWp5vp47pZWcW91w5VzwXlGhteBC1FJ47xdNo70WKALwQmrFeM0tpQ02guEicM4BPRMzstp7fYKNuc2xg7w1CaK5O0j52kAeo2vReJDSI4AOykou9cIq21gIdW0d9aIurg971-1kyxAc9mOG9on06U0fb8x1-mFqJiVTugje3Qty-j7hMJpNmnJf_m84o41uJCujnpH3e8rlNAwZw0MHRs0uR7PL0exyLOzbx096IP-nVoCzPfAztrh93mSW51_knfIfhKmp0w
CitedBy_id crossref_primary_10_3389_fonc_2021_617362
crossref_primary_10_1002_med_21750
crossref_primary_10_3390_ijms23105801
crossref_primary_10_3389_fonc_2022_918954
crossref_primary_10_1093_hmg_ddab370
crossref_primary_10_1177_09603271221150247
crossref_primary_10_1186_s11658_019_0189_2
crossref_primary_10_3389_fcell_2022_1012179
crossref_primary_10_1016_j_critrevonc_2019_03_013
crossref_primary_10_3389_fonc_2020_613679
Cites_doi 10.1007/s11060-014-1575-2
10.1016/j.biocel.2008.05.026
10.18632/oncotarget.3842
10.18632/oncotarget.5642
10.1007/s00432-010-0815-x
10.1097/IGC.0000000000000703
10.1007/s13402-015-0233-9
10.1038/cdd.2016.117
10.18632/oncotarget.10519
10.1097/MPA.0b013e3182962acb
10.1371/journal.pone.0033860
10.1016/j.humpath.2010.05.024
10.1615/CritRevOncog.2015014033
10.18632/oncotarget.10643
10.1186/1868-7083-3-4
10.3892/or.2013.2481
10.1016/j.molcel.2005.12.007
10.1016/j.canlet.2014.10.034
10.1016/j.canlet.2015.11.017
10.1021/pr500497e
10.2217/fon.12.173
10.1186/s12935-014-0112-x
10.1002/jcp.24863
10.3892/ijo.2015.3240
10.1111/j.1582-4934.2008.00482.x
10.1038/43710
10.1016/j.ejca.2014.09.012
10.1089/scd.2011.0695
10.1016/j.oraloncology.2016.02.015
10.1002/ijc.28810
10.1016/j.molonc.2012.09.004
10.3892/ijo.2014.2337
10.1016/j.molonc.2012.09.003
10.1186/s13048-016-0301-4
10.18632/oncotarget.13680
10.1172/JCI69738
10.4161/cc.6.12.4409
10.18632/oncotarget.3735
10.1007/s12253-012-9499-7
10.1182/blood-2007-06-098061
10.1016/j.chemphyslip.2014.04.001
10.1038/sj.onc.1210204
10.1111/dote.12127
10.1074/jbc.M603724200
10.18632/oncotarget.3555
10.1038/srep06226
10.1038/bjc.2014.547
10.1186/1471-2202-12-50
10.1016/j.humpath.2009.12.018
10.1007/s13277-015-3497-9
ContentType Journal Article
Copyright 2018 The Authors. published by John Wiley & Sons Ltd.
2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2018 The Authors. published by John Wiley & Sons Ltd.
– notice: 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
– notice: 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
WIN
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7X7
7XB
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M7P
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
5PM
DOA
DOI 10.1002/cam4.1634
DatabaseName Wiley Open Access
Wiley-Blackwell Backfiles (Open access)
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
Biological Science Collection
AUTh Library subscriptions: ProQuest Central
ProQuest Natural Science Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni Edition)
Biological Science Database
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Publicly Available Content Database
ProQuest Central Student
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest Central (Alumni)
DatabaseTitleList
CrossRef


MEDLINE
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: 24P
  name: Wiley Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: AUTh Library subscriptions: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate WU et al
EISSN 2045-7634
EndPage 4569
ExternalDocumentID oai_doaj_org_article_da44deaa7f5b42479b5b8baf66bc0d36
10_1002_cam4_1634
30091530
CAM41634
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations United States--US
China
GeographicLocations_xml – name: China
– name: United States--US
GrantInformation_xml – fundername: Shenyang Science and Technology Grand
  funderid: 18‐013‐0‐59
– fundername: National Natural Scientific Foundation of China
  funderid: 81472544; 81672700
– fundername: National Natural Scientific Foundation of China
  grantid: 81472544; 81672700
– fundername: Shenyang Science and Technology Grand
  grantid: 18‐013‐0‐59
GroupedDBID 0R~
1OC
24P
31~
53G
5VS
7X7
8-0
8-1
8FE
8FH
8FI
8FJ
AAHHS
AAZKR
ABDBF
ABUWG
ACCFJ
ACXQS
ADBBV
ADKYN
ADRAZ
ADZMN
ADZOD
AEEZP
AENEX
AEQDE
AFKRA
AIWBW
AJBDE
ALAGY
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AOIJS
AVUZU
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
CCPQU
D-8
D-9
DIK
EBS
EJD
FYUFA
GODZA
GROUPED_DOAJ
GX1
HCIFZ
HMCUK
HYE
HZ~
IAO
IHR
KQ8
LK8
M48
M7P
M~E
O9-
OK1
OVD
PIMPY
PQQKQ
PROAC
RPM
TEORI
TUS
UKHRP
WIN
CGR
CUY
CVF
ECM
EIF
ITC
NPM
AAYXX
CITATION
3V.
7XB
8FK
AZQEC
DWQXO
GNUQQ
K9.
PQEST
PQUKI
PRINS
5PM
ID FETCH-LOGICAL-c5754-b7825ccfdd503773233643ddd9887d73e3fa2575751262b008e831e9f222aed13
IEDL.DBID RPM
ISSN 2045-7634
IngestDate Tue Oct 22 15:16:46 EDT 2024
Tue Sep 17 20:57:08 EDT 2024
Thu Oct 10 19:20:45 EDT 2024
Thu Sep 26 15:30:45 EDT 2024
Sat Sep 28 08:26:10 EDT 2024
Sat Aug 24 00:58:33 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 9
Keywords neuroblastoma
ING5
miRNA
histone acetylation
suberoylanilide hydroxamic acid
Language English
License Attribution
2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5754-b7825ccfdd503773233643ddd9887d73e3fa2575751262b008e831e9f222aed13
ORCID 0000-0001-9655-6940
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144157/
PMID 30091530
PQID 2108784115
PQPubID 2032540
PageCount 16
ParticipantIDs doaj_primary_oai_doaj_org_article_da44deaa7f5b42479b5b8baf66bc0d36
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6144157
proquest_journals_2108784115
crossref_primary_10_1002_cam4_1634
pubmed_primary_30091530
wiley_primary_10_1002_cam4_1634_CAM41634
PublicationCentury 2000
PublicationDate September 2018
PublicationDateYYYYMMDD 2018-09-01
PublicationDate_xml – month: 09
  year: 2018
  text: September 2018
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Bognor Regis
– name: Hoboken
PublicationTitle Cancer medicine (Malden, MA)
PublicationTitleAlternate Cancer Med
PublicationYear 2018
Publisher John Wiley & Sons, Inc
John Wiley and Sons Inc
Wiley
Publisher_xml – name: John Wiley & Sons, Inc
– name: John Wiley and Sons Inc
– name: Wiley
References 2017; 8
2015; 36
2009; 41
2015; 6
2015; 38
2017; 24
2013; 42
2014; 27
2012; 18
2011; 12
2016; 280
2011; 3
1999; 401
2015; 8
2014; 44
2016; 56
2013; 9
2014; 135
2016; 7
2009; 13
2014; 4
2006; 21
2015; 356
2015; 20
2010; 136
2015; 112
2017; 10
2015; 230
2008; 28
2006; 26
2013; 30
2011; 42
2014; 14
2007; 6
2014; 13
2014; 181
2006; 281
2012; 6
2008; 111
2012; 7
2014; 50
2016; 48
2014; 120
2016; 26
2012; 21
2007; 26
2014; 124
e_1_2_7_5_1
e_1_2_7_3_1
e_1_2_7_9_1
e_1_2_7_7_1
e_1_2_7_19_1
e_1_2_7_17_1
e_1_2_7_15_1
e_1_2_7_41_1
e_1_2_7_13_1
e_1_2_7_11_1
e_1_2_7_45_1
e_1_2_7_47_1
e_1_2_7_26_1
e_1_2_7_49_1
e_1_2_7_28_1
Lu H (e_1_2_7_27_1) 2016; 7
e_1_2_7_50_1
e_1_2_7_25_1
e_1_2_7_31_1
e_1_2_7_52_1
e_1_2_7_23_1
e_1_2_7_33_1
e_1_2_7_54_1
e_1_2_7_21_1
e_1_2_7_35_1
e_1_2_7_37_1
e_1_2_7_39_1
e_1_2_7_6_1
e_1_2_7_4_1
Zheng H (e_1_2_7_40_1) 2006; 26
e_1_2_7_8_1
e_1_2_7_18_1
e_1_2_7_16_1
Yamamoto S (e_1_2_7_29_1) 2008; 28
e_1_2_7_2_1
e_1_2_7_14_1
e_1_2_7_42_1
e_1_2_7_12_1
e_1_2_7_44_1
e_1_2_7_10_1
e_1_2_7_46_1
e_1_2_7_48_1
e_1_2_7_51_1
e_1_2_7_30_1
e_1_2_7_53_1
Zhao QY (e_1_2_7_43_1) 2015; 8
e_1_2_7_24_1
e_1_2_7_32_1
e_1_2_7_22_1
e_1_2_7_34_1
e_1_2_7_20_1
e_1_2_7_36_1
e_1_2_7_38_1
References_xml – volume: 27
  start-page: 693
  year: 2014
  end-page: 702
  article-title: Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo
  publication-title: Dis Esophagus
– volume: 26
  start-page: 3579
  year: 2006
  end-page: 3583
  article-title: Expressions of MMP‐2, MMP‐9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma
  publication-title: Anticancer Res
– volume: 281
  start-page: 24161
  year: 2006
  end-page: 24170
  article-title: DNA damage‐induced down‐regulation of human Cdc25C and Cdc2 is mediated by cooperation between p53 and maintenance DNA (cytosine‐5) methyltransferase 1
  publication-title: J Biol Chem
– volume: 50
  start-page: 3243
  year: 2014
  end-page: 3261
  article-title: Synergism of arsenic trioxide and MG132 in Raji cells attained by targeting BNIP3, autophagy, and mitochondria with low doses of valproic acid and vincristine
  publication-title: Eur J Cancer
– volume: 42
  start-page: 25
  year: 2011
  end-page: 35
  article-title: The altered expression of ING5 protein is involved in gastric carcinogenesis and subsequent progression
  publication-title: Hum Pathol
– volume: 41
  start-page: 736
  year: 2009
  end-page: 739
  article-title: Zn (II)‐dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A
  publication-title: Int J Biochem Cell Biol
– volume: 401
  start-page: 188
  year: 1999
  end-page: 193
  article-title: Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
  publication-title: Nature
– volume: 6
  start-page: 19552
  year: 2015
  end-page: 19579
  article-title: ING5 suppresses proliferation, apoptosis, migration and invasion, and induces autophagy and differentiation of gastric cancer cells: a good marker for carcinogenesis and subsequent progression
  publication-title: Oncotarget
– volume: 56
  start-page: 32
  year: 2016
  end-page: 39
  article-title: Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs
  publication-title: Oral Oncol
– volume: 8
  start-page: 3156
  year: 2017
  end-page: 3169
  article-title: SAHA and/or MG132 reverse the aggressive phenotypes of glioma cells: an in vitro and vivo study
  publication-title: Oncotarget
– volume: 21
  start-page: 51
  year: 2006
  end-page: 64
  article-title: ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation
  publication-title: Mol Cell
– volume: 7
  start-page: 54596
  year: 2016
  end-page: 54615
  article-title: The down‐regulated ING5 expression in lung cancer: a potential target of gene therapy
  publication-title: Oncotarget
– volume: 48
  start-page: 409
  year: 2016
  end-page: 420
  article-title: Synergistic anticancer effects of cisplatin and histone deacetylase inhibitors (SAHA and TSA) on cholangiocarcinoma cell lines
  publication-title: Int J Oncol
– volume: 135
  start-page: 1721
  year: 2014
  end-page: 1732
  article-title: Simultaneous NF‐κB inhibition and E‐cadherin upregulation mediate mutually synergistic anticancer activity of celastrol and SAHA in vitro and in vivo
  publication-title: Int J Cancer
– volume: 28
  start-page: 1585
  year: 2008
  end-page: 1591
  article-title: Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy‐ associated cell death in chondrosarcoma cell lines
  publication-title: Anticancer Res
– volume: 6
  start-page: 637
  year: 2012
  end-page: 656
  article-title: HDAC inhibitor‐based therapies: can we interpret the code?
  publication-title: Mol Oncol
– volume: 10
  start-page: 1
  year: 2017
  article-title: MiR‐1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression
  publication-title: J Ovarian Res
– volume: 124
  start-page: 30
  year: 2014
  end-page: 39
  article-title: New and emerging HDAC inhibitors for cancer treatment
  publication-title: J Clin Invest
– volume: 36
  start-page: 9347
  year: 2015
  end-page: 9356
  article-title: Suberoylanilide hydroxamic acid enhances chemosensitivity to 5‐fluorouracil in hepatocellular carcinoma via inhibition of thymidylate synthase
  publication-title: Tumour Biol
– volume: 356
  start-page: 828
  year: 2015
  end-page: 836
  article-title: SAHA triggered MET activation contributes to SAHA tolerance in solid cancer cells
  publication-title: Cancer Lett
– volume: 13
  start-page: 4211
  year: 2014
  end-page: 4219
  article-title: SAHA regulates histone acetylation, Butyrylation, and protein expression in neuroblastoma
  publication-title: J Proteome Res
– volume: 18
  start-page: 713
  year: 2012
  end-page: 720
  article-title: SAHA Inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of Cyclin D1 and survivin
  publication-title: Pathol Oncol Res
– volume: 6
  start-page: 10195
  year: 2015
  end-page: 10206
  article-title: The miR‐193a‐3p‐regulated ING5 gene activates the DNA damage response pathway and inhibits multi‐chemoresistance in bladder cancer
  publication-title: Oncotarget
– volume: 21
  start-page: 2508
  year: 2012
  end-page: 2519
  article-title: MicroRNA‐193 pro‐proliferation effects for bone mesenchymal stem cells after low‐level laser irradiation treatment through inhibitor of growth family, member 5
  publication-title: Stem Cells Dev
– volume: 3
  start-page: 4
  year: 2011
  article-title: Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells
  publication-title: Clin Epigenetics
– volume: 44
  start-page: 1745
  year: 2014
  end-page: 1755
  article-title: Suberoylanilide hydroxamic acid‐induced HeLa cell death is closely correlated with oxidative stress and thioredoxin 1 levels
  publication-title: Int J Oncol
– volume: 7
  start-page: e33860
  year: 2012
  article-title: Biodegradable thermosensitive hydrogel for SAHA and DDP delivery: therapeutic effects on oral squamous cell carcinoma xenografts
  publication-title: PLoS ONE
– volume: 13
  start-page: 2115
  year: 2009
  end-page: 2121
  article-title: Prognostic role of global DNA‐methylation and histone acetylation in pT1a clear cell renal carcinoma in partial nephrectomy specimens
  publication-title: J Cell Mol Med
– volume: 20
  start-page: 245
  year: 2015
  end-page: 270
  article-title: Neuroblastoma
  publication-title: Crit Rev Oncog
– volume: 6
  start-page: 16239
  year: 2015
  end-page: 16252
  article-title: ING5 inhibits cancer aggressiveness via preventing EMT and is a potential prognostic biomarker for lung cancer
  publication-title: Oncotarget
– volume: 136
  start-page: 1573
  year: 2010
  end-page: 1578
  article-title: Decreased nuclear expression and increased cytoplasmic expression of ING5 may be linked to tumorigenesis and progression in human head and neck squamous cell carcinoma
  publication-title: J Cancer Res Clin Oncol
– volume: 7
  start-page: 56508
  year: 2016
  end-page: 56525
  article-title: The in vitro and vivo anti‐tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) and MG132 on the aggressive phenotypes of gastric cancer cells
  publication-title: Oncotarget
– volume: 14
  start-page: 112
  year: 2014
  article-title: Effects of suberoylanilide hydroxamic acid (SAHA) combined with paclitaxel (PTX) on paclitaxel‐resistant ovarian cancer cells and insights into the underlying mechanisms
  publication-title: Cancer Cell Int
– volume: 9
  start-page: 255
  year: 2013
  end-page: 269
  article-title: Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials
  publication-title: Future Oncol
– volume: 6
  start-page: 1419
  year: 2007
  end-page: 1425
  article-title: Two distinct controls of mitotic cdk1/cyclin B1 activity requisite for cell growth prior to cell division
  publication-title: Cell Cycle
– volume: 42
  start-page: 1169
  year: 2013
  end-page: 1181
  article-title: Aberrant expression miR‐196a is associated with abnormal apoptosis, invasion, and proliferation of pancreatic cancer cells
  publication-title: Pancreas
– volume: 38
  start-page: 341
  year: 2015
  end-page: 352
  article-title: MYCN concurrence with SAHA‐ induced cell death in human neuroblastoma cells
  publication-title: Cell Oncol (Dordr)
– volume: 280
  start-page: 304
  year: 2016
  end-page: 314
  article-title: More than the genes, the tumor microenvironment in neuroblastoma
  publication-title: Cancer Lett
– volume: 30
  start-page: 560
  year: 2013
  end-page: 566
  article-title: Pin1‐Nanog expression in human glioma is correlated with advanced tumor progression
  publication-title: Oncol Rep
– volume: 120
  start-page: 459
  year: 2014
  end-page: 472
  article-title: Co‐administration of ABT‐737 and SAHA induces apoptosis, mediated by Noxa upregulation, Bax activation and mitochondrial dysfunction in PTEN‐intact malignant human glioma cell lines
  publication-title: J Neurooncol
– volume: 6
  start-page: 38093
  year: 2015
  end-page: 38106
  article-title: Upregulated in Hepatitis B virus‐associated hepatocellular carcinoma cells, miR‐331‐3p promotes proliferation of hepatocellular carcinoma cells by targeting ING5
  publication-title: Oncotarget
– volume: 8
  start-page: 15498
  year: 2015
  end-page: 15505
  article-title: ING5 inhibits epithelial‐mesenchymal transition in breast cancer by suppressing PI3K/Akt pathway
  publication-title: Int J Clin Exp Med
– volume: 24
  start-page: 8
  year: 2017
  end-page: 14
  article-title: p53 on the crossroad between regeneration and cancer
  publication-title: Cell Death Differ
– volume: 4
  start-page: 6226
  year: 2014
  article-title: Histone deacetylases inhibition by SAHA/Vorinostat normalizes the glioma micro‐ environment via xCT equilibration
  publication-title: Sci Rep
– volume: 26
  start-page: 1351
  year: 2007
  end-page: 1356
  article-title: Discovery and development of SAHA as an anticancer agent
  publication-title: Oncogene
– volume: 181
  start-page: 62
  year: 2014
  end-page: 75
  article-title: Mitochondrial alterations in apoptosis
  publication-title: Chem Phys Lipids
– volume: 42
  start-page: 424
  year: 2011
  end-page: 433
  article-title: The nuclear to cytoplasmic shift of ING5 protein during colorectal carcinogenesis with their distinct links to pathologic behaviors of carcinomas
  publication-title: Hum Pathol
– volume: 230
  start-page: 1276
  year: 2015
  end-page: 1289
  article-title: The synergistic effect of SAHA and parthenolide in MDA‐MB231 breast cancer cells
  publication-title: J Cell Physiol
– volume: 26
  start-page: 839
  year: 2016
  end-page: 844
  article-title: Proteasome inhibitor MG132 enhances sensitivity to cisplatin on ovarian carcinoma cells in vitro and in vivo
  publication-title: Int J Gynecol Cancer
– volume: 12
  start-page: 50
  year: 2011
  article-title: Histone deacetylase inhibitors SAHA and sodium butyrate block G1‐to‐S cell cycle progression in neurosphere formation by adult subventricular cells
  publication-title: BMC Neurosci
– volume: 111
  start-page: 1060
  year: 2008
  end-page: 1166
  article-title: Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
  publication-title: Blood
– volume: 6
  start-page: 657
  year: 2012
  end-page: 682
  article-title: Trials with ‘epigenetic’ drugs: an update
  publication-title: Mol Oncol
– volume: 112
  start-page: 112
  year: 2015
  end-page: 121
  article-title: Histone deacetylase inhibitor SAHA epigenetically regulates miR‐17‐92 cluster and MCM7 to upregulate MICA expression in hepatoma
  publication-title: Br J Cancer
– ident: e_1_2_7_31_1
  doi: 10.1007/s11060-014-1575-2
– ident: e_1_2_7_7_1
  doi: 10.1016/j.biocel.2008.05.026
– ident: e_1_2_7_44_1
  doi: 10.18632/oncotarget.3842
– ident: e_1_2_7_47_1
  doi: 10.18632/oncotarget.5642
– ident: e_1_2_7_54_1
  doi: 10.1007/s00432-010-0815-x
– ident: e_1_2_7_33_1
  doi: 10.1097/IGC.0000000000000703
– ident: e_1_2_7_16_1
  doi: 10.1007/s13402-015-0233-9
– ident: e_1_2_7_37_1
  doi: 10.1038/cdd.2016.117
– ident: e_1_2_7_42_1
  doi: 10.18632/oncotarget.10519
– ident: e_1_2_7_49_1
  doi: 10.1097/MPA.0b013e3182962acb
– ident: e_1_2_7_32_1
  doi: 10.1371/journal.pone.0033860
– ident: e_1_2_7_53_1
  doi: 10.1016/j.humpath.2010.05.024
– ident: e_1_2_7_3_1
  doi: 10.1615/CritRevOncog.2015014033
– volume: 7
  start-page: 56508
  year: 2016
  ident: e_1_2_7_27_1
  article-title: The in vitro and vivo anti‐tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) and MG132 on the aggressive phenotypes of gastric cancer cells
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.10643
  contributor:
    fullname: Lu H
– volume: 28
  start-page: 1585
  year: 2008
  ident: e_1_2_7_29_1
  article-title: Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy‐ associated cell death in chondrosarcoma cell lines
  publication-title: Anticancer Res
  contributor:
    fullname: Yamamoto S
– ident: e_1_2_7_4_1
  doi: 10.1186/1868-7083-3-4
– ident: e_1_2_7_41_1
  doi: 10.3892/or.2013.2481
– ident: e_1_2_7_9_1
  doi: 10.1016/j.molcel.2005.12.007
– ident: e_1_2_7_12_1
  doi: 10.1016/j.canlet.2014.10.034
– ident: e_1_2_7_2_1
  doi: 10.1016/j.canlet.2015.11.017
– ident: e_1_2_7_17_1
  doi: 10.1021/pr500497e
– volume: 26
  start-page: 3579
  year: 2006
  ident: e_1_2_7_40_1
  article-title: Expressions of MMP‐2, MMP‐9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma
  publication-title: Anticancer Res
  contributor:
    fullname: Zheng H
– ident: e_1_2_7_22_1
  doi: 10.2217/fon.12.173
– ident: e_1_2_7_11_1
  doi: 10.1186/s12935-014-0112-x
– ident: e_1_2_7_26_1
  doi: 10.1002/jcp.24863
– ident: e_1_2_7_23_1
  doi: 10.3892/ijo.2015.3240
– ident: e_1_2_7_51_1
  doi: 10.1111/j.1582-4934.2008.00482.x
– ident: e_1_2_7_5_1
  doi: 10.1038/43710
– ident: e_1_2_7_34_1
  doi: 10.1016/j.ejca.2014.09.012
– ident: e_1_2_7_50_1
  doi: 10.1089/scd.2011.0695
– ident: e_1_2_7_14_1
  doi: 10.1016/j.oraloncology.2016.02.015
– ident: e_1_2_7_8_1
  doi: 10.1002/ijc.28810
– ident: e_1_2_7_20_1
  doi: 10.1016/j.molonc.2012.09.004
– ident: e_1_2_7_10_1
  doi: 10.3892/ijo.2014.2337
– ident: e_1_2_7_21_1
  doi: 10.1016/j.molonc.2012.09.003
– ident: e_1_2_7_46_1
  doi: 10.1186/s13048-016-0301-4
– ident: e_1_2_7_18_1
  doi: 10.18632/oncotarget.13680
– ident: e_1_2_7_19_1
  doi: 10.1172/JCI69738
– ident: e_1_2_7_38_1
  doi: 10.4161/cc.6.12.4409
– ident: e_1_2_7_45_1
  doi: 10.18632/oncotarget.3735
– ident: e_1_2_7_28_1
  doi: 10.1007/s12253-012-9499-7
– ident: e_1_2_7_30_1
  doi: 10.1182/blood-2007-06-098061
– ident: e_1_2_7_39_1
  doi: 10.1016/j.chemphyslip.2014.04.001
– ident: e_1_2_7_6_1
  doi: 10.1038/sj.onc.1210204
– ident: e_1_2_7_24_1
  doi: 10.1111/dote.12127
– volume: 8
  start-page: 15498
  year: 2015
  ident: e_1_2_7_43_1
  article-title: ING5 inhibits epithelial‐mesenchymal transition in breast cancer by suppressing PI3K/Akt pathway
  publication-title: Int J Clin Exp Med
  contributor:
    fullname: Zhao QY
– ident: e_1_2_7_36_1
  doi: 10.1074/jbc.M603724200
– ident: e_1_2_7_48_1
  doi: 10.18632/oncotarget.3555
– ident: e_1_2_7_15_1
  doi: 10.1038/srep06226
– ident: e_1_2_7_13_1
  doi: 10.1038/bjc.2014.547
– ident: e_1_2_7_35_1
  doi: 10.1186/1471-2202-12-50
– ident: e_1_2_7_52_1
  doi: 10.1016/j.humpath.2009.12.018
– ident: e_1_2_7_25_1
  doi: 10.1007/s13277-015-3497-9
SSID ssj0000702671
Score 2.208039
Snippet Neuroblastoma is the most common extracranial solid neuroendocrine cancer and is one of the leading causes of death in children. To improve clinical outcomes...
Abstract Neuroblastoma is the most common extracranial solid neuroendocrine cancer and is one of the leading causes of death in children. To improve clinical...
Abstract Neuroblastoma is the most common extracranial solid neuroendocrine cancer and is one of the leading causes of death in children. To improve clinical...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
wiley
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 4554
SubjectTerms Acetylation
Animals
Antineoplastic Agents - pharmacology
Apoptosis
Apoptosis - drug effects
Apoptosis - genetics
BAX protein
Biomarkers
Cancer Biology
Caspase
Cell cycle
Cell Cycle - drug effects
Cell Line, Tumor
Cell proliferation
Chromatin
Cyclin-dependent kinase inhibitor p21
Disease Models, Animal
Energy Metabolism - drug effects
Gene expression
Gene Expression Regulation, Neoplastic - drug effects
Glucose metabolism
histone acetylation
Histone deacetylase
Histone Deacetylase Inhibitors - pharmacology
Histones - metabolism
Humans
Hydroxamic acid
Immunohistochemistry
ING5
Leupeptins - pharmacology
Mice
MicroRNAs - genetics
miRNA
Models, Biological
Myc protein
Neuroblastoma
Neuroblastoma - drug therapy
Neuroblastoma - genetics
Neuroblastoma - metabolism
Neuroblasts
Neuroendocrine tumors
Original Research
p53 Protein
Phenotypes
Proteasome inhibitors
Proteasomes
PTEN protein
Signal Transduction
suberoylanilide hydroxamic acid
Transcription Factors - genetics
Transcription Factors - metabolism
Tumor Suppressor Proteins - genetics
Tumor Suppressor Proteins - metabolism
Vorinostat - pharmacology
Xenograft Model Antitumor Assays
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NT9wwEB0hDhUXxDdplypCHLgE7NiOk-MWFShiORWJmzWOHbESZCtYpHLjJ_Q39pd07GTRrlrUC9fEUux5seeNZvwG4IChRKYszziR5UxyLzIaiZlCW6AQnvEyXE4eXRXn1_LiRt3MtfoKNWGdPHBnuGOHUjqPqBtlZS51ZZUtLTZFYWvmRCe2zaq5YCqewTp0VuIzKSGWH9d4L4-IfMgFBxR1-v9FLv-ukZznrtH5nK7Bas8a02E323VY8u0GfBj1efFNuPx2daZ-v_yK90CIQ6YYGkAE3Q1L7Hg6uce0L9xIJ036-BSqRJ7vsB3fjZ1Pb5_dw-RnaEyfYj12W3B9-vX7yXnW90nIaiJbMrPk5VVdN84pJrQWuRDEM5xzFZ0gTgsvGqSdGTIseZHTPit9KbivGuIG6B0X27DcTlq_CylFIxQ_NIXPbS1tlVtEVtVci8Jh5RwmsD8znvnRyWGYTvg4N8HCJlg4gS_BrK8DgoJ1fEC4mh5X8z9cExjMQDH9tno0hHQZEqVcJbDT4fP6FUFskY5vloBeQG5hGotv2vFtFNQuYlSpEziMGL-9MnMyHAUGKz--xxI_wQrRr7KrWBvA8vThye8RxZnaz_Fv_gMxjfwU
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: AUTh Library subscriptions: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB7BVkJcqvIOLShCHLiEOn4lOaG2aimIXSFEpd6scezQldqk3d1K9MZP4DfySxgn3oUVj2tiKc6MZ_yNZ_wNwEuGEpmyeZYTWM5k7kVGIzFTaDUK4VlehsvJ44k-PpHvT9VpPHCbx7LKpU_sHbXr6nBGvkuhSRlyZLl6c3mVha5RIbsaW2jchg1OkQIbwcb-4eTjp9UpCy1orot8SSnE-G6NF_I1gRC5thH1fP1_A5l_1kr-jmH7TehoCzYjekz3BnXfg1u-vQ93xjE__gA-vJu8VT--fe_vgxCWTDE0ggj8G5ZQ8qK7wDQWcKRdk86vQ7XIzTm20_Op8-nZjZt1X0OD-hTrqXsIJ0eHnw-Os9gvIasJdMnM0m6v6rpxTjFRFIILQXjDOVeRJ3GF8KJBstCQaeGak72VvhS5rxrCCOhdLh7BqO1a_wRSikoojmi057aWtuIWkVV1XgjtsHIOE3ixFJ65HGgxzECAzE2QsAkSTmA_iHU1IDBZ9w-62RcTDcM4lNJ5xKJRVnJZVFbZ0mKjta2ZEzqBnaVSTDSvufm1GBJ4POhn9RVBqJHcOEugWNPc2jTW37TTs55YW_fRZZHAq17H__4zc7A3DkhWPv3_7LbhLgGscqhJ24HRYnbtnxGIWdjncaX-BL3281I
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrZ1Lb9QwEMdHpUiIC-JNoEUR4sAlJY5fyaFCbUUpiO2JlXqzxrFDV9omsN1K3Rsfgc_YT8LYSaquKDeuiaMkM378Rh7_B-BtjgJzaVnGCJYzwTzPqCVmEq1Czn3OynA4eXKsjqbiy4k82YCxxuZgwPNbQ7tQT2q6mO9c_lx9oAG_OwiIvq_xTOwQV4g7cLcQFKCHDL6B8uOErEOZJTbqCt18Ym01iqL9t5Hm3wmTN0E2rkSHD-HBgJDpXu_zR7Dh28dwbzJskj-Br5-PP8mrX7_joRACyhRDNYggwmEJlZfdGaZDFkfaNen5RUgZWc2xnc1nzqenK7foLkOV-hTrmXsK08OP3w6OsqFoQlYTeYnM0pIv67pxTuZca15wTtDhnKtoOnGae94gDdOw3VKoggZd6UvOfNUQKKB3jD-DzbZr_QtIKTShYKJRvrC1sFVhEfOqZporh5VzmMCb0XjmR6-NYXoV5MIEC5tg4QT2g1mvGwQ563ihW3w3w-gwDoVwHlE30opC6MpKW1pslLJ17rhKYGt0ihm7iKFgtQy7pkwm8Lz3z_VbOKEjzeV5AnrNc2ufsX6nnZ1GdW0VQ0ydwLvo43__mTnYmwScFS__xy--gvvEYmWfvrYFm8vFhd8m3lna17E3_wH6AgGI
  priority: 102
  providerName: Scholars Portal
– databaseName: Wiley Open Access
  dbid: 24P
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Nb9QwEB2VIiEuiG8CBUWIA5fQxF9JxKlUlILYigOVerPGsdOu1CZodyvRGz-B38gvYcbJBlaAxDVxlGTGz37jGT8DvMhRYa5dkRVEljNVBJlRS8w0OoNShryoeHPy7MgcHqsPJ_pkC16v98IM-hDTghsjI47XDHB0y91foqENXqhXxCbUNbjOijEsnC_Up2mBhfqyMDHgYsX1jHCk1spCudidnt6Yj6Js_9-45p8lk79T2TgXHdyGWyOJTPcGr9-BrdDdhRuzMU1-Dz6-P3qnf3z7HreFEKVMkc-DYBkOR2R51V9gOtZxpH2bLi-5aOTqHLv5-dyH9OzKL_qvfE59is3c34fjg7ef9w-z8diErCHupTJHk75umtZ7ncuylEJKoh3e-5oGFF_KIFskoHLCRRhBsKtCJYtQt0QVMPhCPoDtru_CI0gpOKFwojVBuEa5WjjEvG6KUhqPtfeYwPO18eyXQR3DDjrIwrKFLVs4gTds1qkBC1rHC_3i1I74sB6V8gGxbLVTQpW1065y2BrjmtxLk8DO2il2RNnSUrhacd600Ak8HPwzvUUSeaTRPE-g3PDcxmds3unmZ1Ff28Qgs0zgZfTxv__M7u_NmNCqx__f9AncJM5VDWVqO7C9WlyGp8RrVu5Z7L8_AYTK88E
  priority: 102
  providerName: Wiley-Blackwell
Title ING5‐mediated antineuroblastoma effects of suberoylanilide hydroxamic acid
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcam4.1634
https://www.ncbi.nlm.nih.gov/pubmed/30091530
https://www.proquest.com/docview/2108784115
https://pubmed.ncbi.nlm.nih.gov/PMC6144157
https://doaj.org/article/da44deaa7f5b42479b5b8baf66bc0d36
Volume 7
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB51i4S4IN4EyipCHLhkN47tODm2qz5AZLVCVNpb5FfaSLtJtd1K9MZP4DfySxg7SdUVcOHiQ2LJzjzsb-LPMwAfYslkzBWJCILliBFLI-wpIy5VKim1Mcnc5eRinp6ds89LvtwDPtyF8aR9repJs1pPmvrScyuv1no68MSmi2KW-ihATEcwQgO9F6L75Ve4okpkyCIUJ1Mt12yCuMPV4KGIKdDJ451tyGfr_xvE_JMpeR_B-i3o5Ak87rFjeNjN8Sns2eYZPCz60_Hn8OXT_JT_-vHT3wZBJBlKVwbCZd9QiJG37VqGPX0jbKvw-sZxRW5XsqlXtbHh5a3ZtN9defpQ6tq8gPOT42-zs6ivlhBphFwsUrjXc60rY3hMhaAJpYg2jDE5riNGUEsrif7pzlmSNEFvy2xGic0rRAjSGkJfwn7TNvY1hBiTYBRRpTZRmqk8UVLGuSaCpkbmxsgA3g_CK6-6pBhll_44KZ2wSyfsAI6cWO86uDzW_kG7uSh7bZZGMmaslKLiiiVM5IqrTMkqTZWODU0DOBiUUvbOdV1ilJq541LCA3jV6edulEG_AYgdze1MY_cNWplPq91bVQAfvY7__WXl7LBwOJa9-e9B3sIjRF5ZR1Y7gP3t5sa-Q3SzVWMYJWyBrViKMTw4Op4vvo79nwJsT5cE24JlY2_zvwGKNwEJ
link.rule.ids 230,315,730,783,787,867,888,2109,2228,11574,12068,21400,24330,27936,27937,31731,33756,43322,43817,46064,46488,50826,50935,53804,53806,74073,74630
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB5BKwEXVF4l0EKEOHAJTfxKcqraqmWB7gqhVurNGscOXalNyu5Wojd-Ar-xv6TjxLtlxeOaWIoz4xl_4xl_A_A2RYGpNFmSEVhOROZ4QiMxkWgUcu7SrPCXk4cjNTgWn07kSThwm4ayyrlP7By1bSt_Rr5FoUnhc2SZ3L74nviuUT67Glpo3IVVT1VFwdfq7v7oy9fFKQstaKbybE4plLKtCs_FewIhYmkj6vj6_wYy_6yV_B3DdpvQwRo8DOgx3unV_QjuuOYx3BuG_PgTOPw4-iCvf_7q7oMQlozRN4Lw_BuGUPKsPcc4FHDEbR1PL321yNUZNuOzsXXx6ZWdtD98g_oYq7F9CscH-0d7gyT0S0gqAl0iMbTby6qqrZUpz3POOCe8Ya0tyZPYnDteI1moz7QwxcjeClfwzJU1YQR0NuPPYKVpG_ccYopKKI6olWOmEqZkBjEtqyznymJpLUbwZi48fdHTYuieAJlpL2HtJRzBrhfrYoBnsu4etJNvOhiGtiiEdYh5LY1gIi-NNIXBWilTpZarCDbmStHBvKb6djFEsN7rZ_EVTqiR3HgaQb6kuaVpLL9pxqcdsbbqoss8gnedjv_9Z3pvZ-iRrHjx_9m9hvuDo-GhJu1_fgkPCGwVfX3aBqzMJpdukwDNzLwKq_YGcZf2TA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB7BVqq4IN5NKRAhDlzCxrFjJyfUli7lsasKUak3axw7dKU2aXe3Er3xE_iN_BLGiXdhxeOaWIozz2884xmAFykKTHPDEkZgORHM8YRWYpKjkci5S1nhLyePJ_LwWLw_yU9C_dM8lFUubWJnqG1b-TPyIYUmhc-RsXxYh7KIozej1xeXiZ8g5TOtYZzGTdhQQvJ0ABt7B5OjT6sTFxLuTCq2bC-UZsMKz8UrAiRizSl1vfv_Bjj_rJv8Hc92Dml0B24HJBnv9qy_Czdccw82xyFXfh8-vpu8zX98-97dDSFcGaMfCuF7cRhCzIv2HONQzBG3dTy_8pUj12fYTM-m1sWn13bWfvXD6mOspvYBHI8OPu8fJmF2QlIRABOJIc-fV1VtbZ5ypXjGOWEPa21JVsUq7niNpK0-65LJjHSvcAVnrqwJL6CzjD-EQdM2bgtiilAopqily0wlTJkZxLSsmOLSYmktRvB8STx90bfI0H0z5Ex7CmtP4Qj2PFlXC3xX6-5BO_uig5Joi0JYh6jq3IhMqNLkpjBYS2mq1HIZwc6SKTqo2lz_EowIHvX8WX2FE4Ikk55GoNY4t7aN9TfN9LRrsi27SFNF8LLj8b__TO_vjj2qFdv_390z2CSB1cT8D4_hFuGuoi9V24HBYnblnhC2WZinQWh_Asf8-no
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=ING5%E2%80%90mediated+antineuroblastoma+effects+of+suberoylanilide+hydroxamic+acid&rft.jtitle=Cancer+medicine+%28Malden%2C+MA%29&rft.au=Ji%E2%80%90cheng+Wu&rft.au=Hua%E2%80%90mao+Jiang&rft.au=Xiang%E2%80%90hong+Yang&rft.au=Hua%E2%80%90chuan+Zheng&rft.date=2018-09-01&rft.pub=Wiley&rft.eissn=2045-7634&rft.volume=7&rft.issue=9&rft.spage=4554&rft.epage=4569&rft_id=info:doi/10.1002%2Fcam4.1634&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_da44deaa7f5b42479b5b8baf66bc0d36
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-7634&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-7634&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-7634&client=summon